Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher, Janssen Biotech to Develop CDx for Lung Cancer, Other Indications

NEW YORK – Thermo Fisher Scientific said on Thursday that it has teamed up with Janssen Biotech, a member of Johnson & Johnson's Janssen Pharmaceutical Companies, to develop a companion diagnostic test to support clinical trial enrollment of cancer patients.

Under the deal, scientists at Thermo Fisher and Janssen Research & Development will initially validate biomarkers for use with the Thermo Fisher Oncomine Dx Target Test to identify non-small cell lung cancer (NSCLC) patients for enrollment into clinical trials. The firms may add other cancer indications later on.

The Oncomine Dx Target Test is a next-gen sequencing assay that covers 46 cancer biomarkers. It was approved by the US Food and Drug Administration as a CDx for NSCLC in 2017 and requires only small amounts of DNA or RNA, according to the company.

Since then, Thermo Fisher has struck agreements with several pharmaceutical firms, including Eli Lilly, Daiichi Sankyo, and Takeda Pharmaceuticals, to use the test as a CDx in clinical trials and drug development programs.

"We are confident that this approach to patient stratification helps expedite drug development initiatives which ultimately are designed to promote better health outcomes through targeted therapies," said Peter Silvester, senior VP and president of life sciences solutions at Thermo Fisher Scientific, in a statement.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.